Retinal Layer Thickness Correlates with Plasma Biomarkers in Individuals at Risk for Alzheimer’s Disease

Category	Detail
Condition	Alzheimer’s Disease (AD)
Key Mechanisms	Association of retinal layer thickness with plasma biomarkers indicating neurodegeneration and amyloidosis.
Target Population	Cognitively normal adults at increased risk for AD, characterized by low plasma Aβ42/40 ratio.
Care Setting	Research setting, specifically a brain aging cohort.

Thinner inner nuclear layer (INL) and ganglion cell layer (GCL) correlate with higher levels of p-tau217 and GFAP.
Study utilized spectral-domain optical coherence tomography (SD-OCT) for retinal measurements.
Findings suggest potential for retinal imaging as a complementary tool to plasma biomarkers for early AD risk assessment.
Exploratory pilot study with a small sample size (11 participants).
Need for larger, longitudinal studies to validate preliminary findings.

Use of plasma biomarkers such as Aβ42/40, p-tau217, and GFAP for assessing AD risk.

Consider retinal imaging as a non-invasive method for monitoring individuals at risk for AD.

Regular assessment of plasma biomarkers and retinal layer thickness in at-risk populations.

Potential for misclassification of cognitive status based on plasma biomarker cut-offs.

Cognitively normal adults with a pathological Aβ42/40 ratio indicating increased risk for AD.

Current study does not provide direct treatment recommendations; focuses on risk assessment.

Incorporate retinal imaging in the evaluation of individuals at risk for AD.
Utilize a combination of plasma biomarkers and retinal measurements for comprehensive risk assessment.

Clinical Scorecard: Retinal Layer Thickness Correlates with Plasma Biomarkers in Individuals at Risk for Alzheimer’s Disease